{"nctId":"NCT00331773","briefTitle":"Radiation Therapy in Treating Patients With Stage II Prostate Cancer","startDateStruct":{"date":"2006-04","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":1116,"armGroups":[{"label":"Conventional 3D-CRT","type":"ACTIVE_COMPARATOR","interventionNames":["Radiation: Conventional 3D-CRT or IMRT"]},{"label":"Hypofractionated 3D-CRT","type":"EXPERIMENTAL","interventionNames":["Radiation: Hypofractionated 3D-CRT or IMRT"]}],"interventions":[{"name":"Conventional 3D-CRT or IMRT","otherNames":["3-dimensional conformal radiation therapy","Intensity-modulated radiation therapy (IMRT)"]},{"name":"Hypofractionated 3D-CRT or IMRT","otherNames":["Hypofractionated 3-dimensional conformal radiation therapy","Intensity-modulated radiation therapy (IMRT)"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the prostate within the past 6 months\n\n  * Clinical stage T1-2c\n* Combined Gleason score 2-6\n* Prostate-specific antigen (PSA) \\< 10 ng/mL within the past 6 months\n\n  * PSA evaluated at least 10 days after prostate biopsy\n  * For patients who received finasteride, PSA evaluated at least 30 after completion of finasteride\n  * For patients who received dutasteride, PSA evaluated at least 90 after completion of dutasteride\n* No regional lymph node involvement\n* No distant metastases\n\nPATIENT CHARACTERISTICS:\n\n* Zubrod performance status 0-1\n* No unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months\n* No transmural myocardial infarction within the past 6 months\n* No acute bacterial or fungal infection requiring IV antibiotics\n* No chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study treatment\n* No hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\n* No known AIDS\n* No prior or concurrent lymphomatous/hematogenous malignancy or other invasive malignancy except nonmelanomatous skin cancer or any other cancer for which the patient has been continually disease-free for ≥ 5 years (e.g., carcinoma in situ of the bladder or oral cavity)\n* No other severe, active comorbidity\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior radical prostatectomy or cryosurgery for prostate cancer\n* No prior hormonal therapy, including any of the following:\n\n  * Luteinizing hormone-releasing hormone agonists (e.g., goserelin or leuprolide)\n  * Antiandrogens (e.g., flutamide or bicalutamide)\n  * Estrogens \\[e.g., diethylstilbestrol (DES)\\]\n  * Surgical castration (bilateral orchiectomy)\n* No prior pelvic radiotherapy or prostate brachytherapy\n* No prior or concurrent cytotoxic chemotherapy for prostate cancer\n* At least 30 days since prior finasteride\n* At least 90 days since prior dutasteride\n* No concurrent neoadjuvant or adjuvant hormonal therapy\n* Concurrent warfarin or other blood-thinning agents allowed","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Five-year Disease-free Survival (DFS) Rate","description":"Five-year rates are estimated by the Kaplan-Meier method. DFS events included local progression, distant metastatic progression, biochemical recurrence as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, or death from any cause. Patients who experienced second primary cancers remained under observation for DFS events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Five-year Local Progression Rate","description":"Clinical criteria for local recurrence are progression (increase in palpable abnormality) at any time, failure of regression of the palpable tumor by 2 years, and redevelopment of a palpable abnormality after complete disappearance of previous abnormalities. Histologic criteria for local recurrence are presence of prostatic carcinoma upon biopsy and positive biopsy of the palpably normal prostate more than 2 years after the start of treatment. The arms were not statistically compared because of an insufficient number of events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Five-year Disease-specific Survival Rate","description":"An event was death in association with any of the following conditions:\n\n* Primary cause of death certified as due to prostate cancer\n* Further clinical tumor progression occurring after initiation of \"salvage\" anti-tumor (e.g., (androgen suppression) therapy\n* A rise (that exceeds 1.0 ng/mL) in the serum prostate-specific antigen (PSA) level on at least two consecutive occasions that occurs during or after \"salvage\" androgen suppression therapy\n* Disease progression in the absence of any anti-tumor therapy\n* Death from a complication of therapy, irrespective of disease status. The arms were not statistically compared because of an insufficient number of events.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Five-year PSA Failure Rate","description":"Five-year rates are shown (cumulative incidence estimates). Note, although the protocol calls this endpoint \"Freedom from biochemical recurrence\", it defines the endpoint as \"The time to PSA failure\". An event for PSA, i.e. biochemical, failure was the first of the following: initiation of non-protocol (e.g., salvage) hormone therapy, or an increase in PSA of at least 2 ng/mL. Time to biochemical failure was measured from study entry until the date of failure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Five-year Overall Survival Rate","description":"Five-year rates Kaplan-Meier estimates. Overall survival (OS) was measured from study entry until the date of death. Patients still alive at the time of analysis were censored at the date of last follow-up","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.2","spread":null},{"groupId":"OG001","value":"92.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Patients With GU and GI Acute and Late Toxicity","description":"The frequency of genitourinary (GU) and gastrointestinal (GI) adverse events as defined and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3) were compared between treatment arms. Acute toxicity was defined as any toxicity beginning within 90 days of completion of RT, and late toxicity was defined as any toxicity beginning more than 90 days after the completion of RT. Acute and late GU and GI toxicity rates were tabulated and reported in two ways: dichotomized as \\< grade 2 vs ≥ grade 2, and dichotomized as \\< grade 3 vs ≥ grade 3. Higher grade indicates more severity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Disease-specific HRQOL Change in Expanded Prostate Cancer Index Composite (EPIC); the Utilization of Sexual Medications/Devices Supplements the EPIC","description":"Prostate cancer (PC) Health-Related Quality of Life (HRQOL) outcomes as measured by change over time in the Expanded Prostate Cancer Index Composite \\[EPIC\\], a PC HRQOL instrument measuring a broad spectrum of urinary, bowel, and sexual symptoms related to radiotherapy, is compared between arms. The EPIC questionnaire was grouped into four domains (bowel, urinary, sexual, hormonal), each with a score ranging from 0 (worst) to 100 (best), and was assessed at baseline, 6, 12, and 24 months, and 5 years. The difference in score from baseline to each time point was calculated and the Wilcoxon test statistic was used to test the null hypothesis that responses are the same across the two treatment arms vs. the alternative hypothesis that they are different, using a 2-sided alpha of 0.05 at each timepoint, resulting in an alpha of 0.0125 for each domain. Each row refers to a separate analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":"12.1"},{"groupId":"OG001","value":"-3.7","spread":"11.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"10.5"},{"groupId":"OG001","value":"-1.5","spread":"11.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"20.9"},{"groupId":"OG001","value":"-7.8","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"10.5"},{"groupId":"OG001","value":"-1.8","spread":"10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"11.4"},{"groupId":"OG001","value":"-7.5","spread":"14.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"10.4"},{"groupId":"OG001","value":"-1.8","spread":"13.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.1","spread":"19.7"},{"groupId":"OG001","value":"-8.4","spread":"20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"8.5"},{"groupId":"OG001","value":"-1.6","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"12.4"},{"groupId":"OG001","value":"-6","spread":"12.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"10.6"},{"groupId":"OG001","value":"-0.7","spread":"12.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"21.1"},{"groupId":"OG001","value":"-10.4","spread":"21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"9.5"},{"groupId":"OG001","value":"-1.7","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"11.8"},{"groupId":"OG001","value":"-5.2","spread":"12.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.4"},{"groupId":"OG001","value":"-3.1","spread":"15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"22.1"},{"groupId":"OG001","value":"-15.7","spread":"24.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"10.3"},{"groupId":"OG001","value":"-2.1","spread":"10.4"}]}]}]},{"type":"SECONDARY","title":"The Utilization of Sexual Medications/Devices Questionaire","description":"The Utilization of Sexual Medications/Devices questionaire is designed to assess the use of erectile aids among patients treated for prostate cancer. This instrument is used to complement the sexual symptom domain in the EPIC. The percentage of \"Yes\" responses to the following questions are reported: \"Do you have a penile prosthesis\", \"Have you used an medications or devices to aid or improve erections?\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.5","spread":null},{"groupId":"OG001","value":"23.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Assessment of Anxiety and Depression Using the HSCL-25","description":"Anxiety and depression were measured with the Hopkins Symptom Checklist (HSCL-25). It consists of 25 items: Part I of the HSCL-25 has 10 items for anxiety symptoms; Part II has 15 items for depression symptoms. The scale for each question includes four categories of response (\"Not at all,\" \"A little,\" \"Quite a bit,\" \"Extremely,\" rated 1 to 4, respectively). Two scores are calculated: the total score is the average of all 25 items and ranges from 0 to 100. A higher score indicates worse symptoms. The HSCL-25 tool was assessed at baseline, 6 months, 12 months, 24 months, and 5 years. For each patient, the change in score from baseline to the time point is calculated by subtracting the baseline value from the time point value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"7.8"},{"groupId":"OG001","value":"31.8","spread":"8.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"7.3"},{"groupId":"OG001","value":"32.2","spread":"9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.1","spread":"7.5"},{"groupId":"OG001","value":"31.7","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":"7.1"},{"groupId":"OG001","value":"32.1","spread":"7.9"}]}]}]},{"type":"SECONDARY","title":"EQ-5D Scores","description":"The EQ-5D is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 3 problem levels (1-none, 2-moderate, 3-extreme). Health states are defined by the combination of the leveled responses to the 5 dimensions, generating 243 health states to which unconsciousness and death are added. The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm 10-point interval scale. Worst imaginable health state is scored as 0 at the bottom of the scale, and best imaginable health state is scored as 100 at the top. Both the 5-item index score and the VAS score are transformed into a utility score between 0 -Worst health stat and 1 -Best health state. A two-sided Wilcoxon test with alpha 0.05 was used due to the skewed, thus non-normal, nature of the data.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"85.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"81.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"85.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.0","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Trade-off Between Disease-free Survival and Quality of Life.","description":"To examine trade-offs between the survival time and QOL, we were to combine them for each patient into two single measurements: quality adjusted live year (QALY) and quality adjusted disease-free survival year (QADFSY). We were to use Glasziou's multiple health-state (Q-TWiST) models to use the repeated measures of EQ-5D.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Statistical Modeling of Genomic Biomarkers","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Collection of Paraffin-embedded Tissue Block, Serum, Plasma, and Buffy Coat Cells for Future Translational Research Analyses","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":534},"commonTop":["Pollakiuria","Erectile dysfunction NOS","Diarrhea NOS","Fatigue","Proctitis NOS"]}}}